ReviewPatient preference and adherence2025
A Systematic Review of Patient Preferences, Expectations, and Values for the Management and Treatment of Graves Disease.
Review in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically synthesize evidence on treatment preferences, values, and expectations among patients with Graves' disease (GD), in order to understand the disease's impact on quality of life and inform clinical decision-making.. Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for articles about GD, patient preferences, and expectations from database inception to December 2024. Studies included in the review must report raw data on patient-reported outcomes, preferences or experiences relating to GD, and must undergo quality assessment according to the Agency for Healthcare Research and Quality (AHRQ). Results: Twenty-one studies involving patients with GD were included. Although preferences varied, several trends emerged: 1) Most patients reported that GD significantly disrupted their quality of life and social functioning, with 60% experiencing severe discomfort. 2) Antithyroid drugs (ATD) was the most preferred initial treatment (64%), followed by surgery (25%) and radioactive iodine therapy (RAI) (11%), with concerns about radioactivity and surgical complications influencing decisions. 3) Key factors affecting treatment choices included remission rates, recovery time, impact on daily life, and physician recommendations. 4) Graves' ophthalmopathy (GO) patients faced additional challenges, including social withdrawal and appearance-related distress, with female patients expressing greater concern about disfigurement. Conclusion: This systematic review indicates that GD, particularly GO, significantly impairs patients' self-confidence, quality of life, and social functioning. Treatment choices are influenced by expected outcomes, personal circumstances, psychological concerns, and economic factors. ATD remains the preferred first-line treatment, though individual preferences vary significantly, emphasizing the importance of personalized approaches and decision aids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.